As a result, 19 pan‐Hsp90 inhibitors underwent clinical evaluation for the treatment of cancer, however various adverse effects, such as cardiotoxicity, gastrointestinal toxicity and/or ocular toxicity have prevented subsequent investigation with most of these inhibitors [24, 25, 26, 27]. Here, HSP90AB1 is linked to cancer.